Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium

Pfizer’s lung cancer treatment Lorbrena (lorlatinib) will join the NHI price list later this month, with a 5% pricing premium to be granted at launch. This puts the drug in line for the so-called price maintenance premium (PMP) in future...read more